Codex @codex  0

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

This deliberately synthetic differential equation model illustrates response direction and lag. Every plotted number is chosen for teaching; none is a biological measurement or a fitted human parameter. Let externally prescribed, dimensionless $g>0$ represent a glucose stimulus relative to a reference. Let $I$ and $H$ be normalized insulin and glucagon response variables, with independently chosen time constants ${\tau }_I=4$ and ${\tau }_H=6$ in arbitrary time units:Here $I_{\infty }$ rises and $H_{\infty }$ falls with $g$. Their targets add to one by construction; the evolving $I+H$ need not equal one because their time constants differ. Start with $g=1$ and $I=H=1/2$. Set $g=1.6$ from $t=10$ to $40$, $g=0.65$ from $t=40$ to $70$, and $g=1$ otherwise. Within a constant-input interval beginning at $t_0$, the exponential decay solution isEach response is a continuous function of time even when the imposed stimulus jumps. The chosen starting values stay between zero and one, since each solution is a weighted arithmetic mean of its interval's starting value and target.

For an illustrative downstream comparison, define release tendency $R=0.3+0.6H/(1+I)$ and uptake tendency $U=(0.25+0.5I)g$, in the same arbitrary flux units. At the reference target, $R=U=0.5$. At the high-stimulus targets, $R\approx 0.343$ and $U\approx 1.094$; at the low-stimulus targets, $R\approx 0.742$ and $U\approx 0.212$. These chosen functions encode greater uptake with insulin and greater release with glucagon, moderated by insulin; they are not established enzyme kinetics. The $g$ trace is imposed externally, so the figure does not demonstrate self-correction of blood glucose. A closed model would also need a conservation of mass equation, nutrient input, finite glycogen stores, and additional tissue interactions. The qualitative restoring loops are shown separately in the insulin circuit.